الفهرس 
EmbryologyOnly 14 pages are availabe for public view
 |  | from | 195 |  |  |
| | | from | 195 | | |
Abstract
Meningiomas are generally benign, slow growing tumors, representing the second most common central nervous system neoplasm in adults and account for 26% of all primary brain tumors. Tumor recurrence is the major clinical complication of meningiomas, occurring in between 10%-15% and 25%-37% of patients undergoing curative surgery after a 5- to 10-year follow-up period, respectively. However relapses may occur in a high proportion of cases in the first few years following curative surgery. Because of the current dilemma for neurosurgeons and neuropathologists when predicting which patients have a higher incidence of relapse after total resection of a meningioma, molecular biomarkers may further increase prognostic accuracy, though much work remains to be done. Insulin-like growth factor II mRNA binding protein 3 (IMP3), an oncofetal protein and member of the insulin-like growth factor II mRNA binding protein family, three members of this family are known: IMP1, IMP2 and IMP3. It has recently raised attention since it appears to play an important role in cell-migration and adhesion in various malignant neoplasms, resulting in uncontrolled cell proliferation and carcinogenesis. As an oncogene, IMP3 is expressed during the early stages of embryogenesis, with only limited normal expression in postembryonic stages. Current studies reveal a remarkable re-expression of IMP3 in different human malignancies, e.g. in ovarian cancer, non-small cell lung cancer, pancreatic ductal adenocarcinoma, colorectal adenocarcinoma, esophageal adenocarcinoma.